Midsize biotech companies met with White House and HHS officials to argue against two pending CMS pricing models they say could hinder their businesses. The companies’ outreach centers on how reimbursement changes may affect pipeline economics, commercialization timelines, and patient access under evolving Medicare policy. The policy fight is framed as a near-term risk to business planning, particularly for firms that must fund development costs while managing pricing uncertainty. The report indicates the White House and HHS discussions occurred in the last week as companies sought clarity and potential adjustments. The next regulatory steps will determine whether CMS pricing models are recalibrated for categories of specialty products, or whether the current trajectory stands, influencing near-term investor risk assessments.